Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by...

Area of Science:

• Medicinal Chemistry
• Structural Biology
• Drug Discovery

Background:

• Transforming growth factor-β-activated kinase 1 (TAK1) is crucial in inflammatory and immune signaling pathways.
• TAK1 is a promising molecular target for treating inflammatory diseases and cancers.
• Existing type I TAK1 inhibitors provide a foundation for developing new inhibitor classes.

Purpose of the Study:

• To establish a parallel development strategy for type II and c-helix-out TAK1 inhibitors.
• To leverage structure-based drug design (SBDD) for novel TAK1 inhibitor discovery.
• To report the first c-helix-out inhibitor against TAK1.

Main Methods:

• Utilized X-ray crystallography data of a known type I TAK1 inhibitor.
• Employed SBDD by superimposing the type I inhibitor structure onto a multi-kinase type II inhibitor.
• Adapted structural insights from a b-Raf c-helix-out inhibitor to design TAK1 inhibitors.

Main Results:

• Successfully designed and synthesized novel type II and c-helix-out TAK1 inhibitors.
• Confirmed the binding modes of the designed inhibitors through co-crystallization with TAK1.
• Achieved the first discovery of a c-helix-out inhibitor targeting TAK1.

Conclusions:

• The developed SBDD method enables efficient parallel development of diverse TAK1 inhibitor types.
• The novel type II and c-helix-out inhibitors represent promising leads for therapeutic intervention.
• This study expands the chemical space for TAK1-targeted drug discovery.